ECG

Corsano Health launches Cuffless Blood Pressure

Retrieved on: 
Tuesday, August 22, 2023
Validation, EU, Marketing, DEVICE, ISO, Sleep, Health, ECG, ML, Reinier, DRS, Research, Congress, ABPM, Oxygen saturation (medicine), Vital signs, Collection, Thermoregulation, Patient, Blood pressure, AI, Heart rate, ESC, Medtech, Medical device

THE HAGUE, Netherlands, Aug. 22, 2023 /PRNewswire/ -- Today, Corsano Health, a leading MedTech company developing, producing, and marketing medical grade continuous health monitoring announces the addition of Cuffless Blood Pressure measurements to its advanced smart bracelet. 

Key Points: 
  • Corsano Health is launching the company's CardioWatch EU-MDR certified patient monitoring bracelet with Cuffless Non-Invasive Blood Pressure at ESC in Amsterdam.
  • THE HAGUE, Netherlands, Aug. 22, 2023 /PRNewswire/ -- Today, Corsano Health, a leading MedTech company developing, producing, and marketing medical grade continuous health monitoring announces the addition of Cuffless Blood Pressure measurements to its advanced smart bracelet.
  • The Corsano Cuffless Non-Invasive Blood Pressure algorithm has been in development since 2019 based on arterial line and ABPM data recorded from over 500 patients.
  • The Corsano Blood Pressure algorithm was validated according to ISO 81060-2:2019 and the AAMI/ESH/ISO collaboration statement "A Universal Standard for the Validation of Blood Pressure Measuring Devices" 2018.

HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

Retrieved on: 
Thursday, August 17, 2023
Intellectual property, HSCS, Cardiovascular disease, Heart, European Patent Office, ECG, EPO, Death, Patent, European Patent Convention, Artificial intelligence, United, AI, Medical device

Southlake, TX, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces that it has been issued a notice of patent allowance from the European Patent Office.

Key Points: 
  • Southlake, TX, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces that it has been issued a notice of patent allowance from the European Patent Office.
  • To date, HeartSciences has been granted or allowed 41 patents including 9 in the United States.
  • Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “Millions of ECG’s are performed worldwide every week and the ECG is by far the most ubiquitous cardiac test.
  • This latest patent further expands our international coverage and is the latest addition to our extensive patent portfolio.”

EXI and Hyperice Unveil a New Diabetes-Focused Partnership, Announcing Their Joint Vision of Safe and Effective Self-Care for Patients

Retrieved on: 
Wednesday, August 16, 2023
Nursing, Consumer Electronics, Physical Therapy, Technology, Managed Care, Diabetes, Health, Health Technology, Medical Devices, Fitness & Nutrition, Telemedicine, Virtual Medicine, EXI, Medical device, Partnership, ECG, Software, Multimedia, Inflammation, Movement, Science, Pain, Patient, Sport, Joint, RH, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20230816294012/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230816294012/en/
    Hyperice's Normatec dynamic air compression technology utilizes over a decade of science-backed research to provide you with a restorative massage.
  • (Photo: Business Wire)
    Through this partnership, Hyperice’s Normatec dynamic air compression system will be offered through the EXI platform, providing pain relief for its users living with diabetes as a particular focus and multiple long-term health conditions.
  • “At present, if clinicians want to provide patients with devices for home monitoring – an ECG holter monitor, for example – it’s on a short-term loan basis and inhibits positive habit changes,” said Grace McNamara, CEO of EXI.
  • “At EXI, we’ve identified a number of existing high-quality medical-grade consumer products that are backed by science and easy to use.

Viz.ai Receives First De Novo Approval by the FDA for Hypertrophic Cardiomyopathy AI Algorithm

Retrieved on: 
Tuesday, August 15, 2023
Software, Apps, Applications, Medical Devices, Technology, Hospitals, Artificial Intelligence, Health Technology, Surgery, Cardiology, Nursing, FDA, Health, De novo, Prevalence, ECG, Intelligence, Bristol Myers Squibb, BMY, Viz, Hospital, Platform, MD, Hypertrophic cardiomyopathy, Patient, Algorithm, Artificial intelligence, Diagnosis, AI, Atlantic Health System, Automated ECG interpretation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HCM, NYSE, Food, Medical device

The deployment of the algorithm is financially supported by a multi-year agreement with Bristol Myers Squibb (NYSE: BMY) announced in March.

Key Points: 
  • The deployment of the algorithm is financially supported by a multi-year agreement with Bristol Myers Squibb (NYSE: BMY) announced in March.
  • With the use of Viz HCM, which is integrated into the Viz.ai Platform, more patients with suspected HCM can be identified earlier using AI and triaged for diagnosis and further evaluation.
  • “Hypertrophic cardiomyopathy is a devastating disease that is often undetected until it is too late.
  • “We are thrilled with this De Novo approval, which establishes the new FDA category of cardiovascular machine learning-based notification software.

Wearable Computing Market to Hit $244.43 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Thursday, August 17, 2023
Oculus Quest, Virtual reality, Communication, Music, Augmented reality, Microsoft HoloLens, Smartphone, ECG, Microsoft, Bose Corp. v. Consumers Union of United States, Inc., USD, Smartglasses, Computer, VR, Tablet, Samsung Galaxy Z Fold 2, Patient, SAN, Connectivity, Bluetooth, Consumer, Growth, Diagnosis, Jewellery, Samsung Galaxy, Heart rate, ToC, AR, Safety, Mobile phone, Video game, Consumer electronics

Moreover, wearable devices have gained popularity across various sectors, including fitness and healthcare, entertainment, and industrial applications.

Key Points: 
  • Moreover, wearable devices have gained popularity across various sectors, including fitness and healthcare, entertainment, and industrial applications.
  • Key Industry Insights & Findings from the report:
    The fitness trackers product type segment dominated the market with a share of 35.0% in 2022.
  • Bluetooth technology enables wireless communication and data transfer between wearable devices and other devices, such as smartphones, tablets, and computers.
  • This improves efficiency and safety in industrial settings, showcasing the growth potential of wearable computing in the industrial sector.

Wearable Computing Market to Hit $244.43 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Thursday, August 17, 2023
Oculus Quest, Virtual reality, Communication, Music, Augmented reality, Microsoft HoloLens, Smartphone, ECG, Microsoft, Bose Corp. v. Consumers Union of United States, Inc., USD, Smartglasses, Computer, VR, Tablet, Samsung Galaxy Z Fold 2, Patient, SAN, Connectivity, Bluetooth, Consumer, Growth, Diagnosis, Jewellery, Samsung Galaxy, Heart rate, ToC, AR, Safety, Mobile phone, Video game, Consumer electronics

Moreover, wearable devices have gained popularity across various sectors, including fitness and healthcare, entertainment, and industrial applications.

Key Points: 
  • Moreover, wearable devices have gained popularity across various sectors, including fitness and healthcare, entertainment, and industrial applications.
  • Key Industry Insights & Findings from the report:
    The fitness trackers product type segment dominated the market with a share of 35.0% in 2022.
  • Bluetooth technology enables wireless communication and data transfer between wearable devices and other devices, such as smartphones, tablets, and computers.
  • This improves efficiency and safety in industrial settings, showcasing the growth potential of wearable computing in the industrial sector.

CathVision Secures FDA Clearance of First & Only EP Recording System with AI Algorithm to Measure Success of Cardiac Ablation

Retrieved on: 
Tuesday, August 15, 2023
Alvin Benjamin Rubin, Cardiac electrophysiology, Noise, PVI, Atrial fibrillation, NYU, Algorithm, Fidelity Investments, ECG, Department of Medicine – University of Pamplona, Arrhythmia, Signal, Acquisition, Death-inducing signaling complex, Patient, Physician, Electrophysiology, Cardiology, EP, NYU Langone Health, Diagnosis, AF, FDA, Medical device, Medical imaging, Medicine

COPENHAGEN, Denmark, Aug. 15, 2023 /PRNewswire/ -- CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the FDA clearance and commercial availability of the PVI AnalyzerTM and Signal ComplexityTM algorithms. These algorithms are part of the CARDIALYTICSTM suite of artificial intelligence-powered analytics integrated into the ECGenius System.1 

Key Points: 
  • The CARDIALYTICS suite includes:
    PVI Analyzer: a signal-based AI algorithm capable of confirming PVI isolation status across multiple cardiac ablation modalities when physicians treat complex arrhythmias such as atrial fibrillation.
  • Signal Complexity: an algorithm to help physicians visualize and quantify atrial fibrillation (AF) complexity parameters in patients with persistent AF.
  • ECGenius System is now the only EP recording system with an AI algorithm to facilitate electrogram interpretation.
  • With exceptional data from the ECGenius System, intelligent automated analyses can effectively enable physicians to confirm the success of ablation efforts.

Clario and AliveCor collaborate to offer advanced, trial-focused six-lead ECG solutions for monitoring in decentralized clinical trials

Retrieved on: 
Tuesday, August 15, 2023
Partnership, Data collection, ECG, FDA, SVP, Kardia, PII, Clario Tech, Medical device, Mobile phone, Alivecor

PHILADELPHIA, Aug. 15, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today announced an expansion to its collaboration with AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology. This collaboration will enable trial participants to collect medical-grade six-lead ECG readings in the comfort of their own homes through KardiaRx, a clinical-trial-focused app. This technology enables pharmaceutical and biotech customers to consider decentralized and hybrid clinical trial strategies in study protocols that would have otherwise been limited to on-site evaluations.

Key Points: 
  • Clario and AliveCor provide a new trial-participant-friendly solution for cutting-edge, at-home data collection with privacy protection, instrumental in situations where traditional 12-lead ECG cannot be collected.
  • PHILADELPHIA, Aug. 15, 2023 /PRNewswire/ -- Clario , a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today announced an expansion to its collaboration with AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology.
  • This collaboration will enable trial participants to collect medical-grade six-lead ECG readings in the comfort of their own homes through KardiaRx, a clinical-trial-focused app.
  • "Our partnership with AliveCor is a game-changer for at-home ECG data collection," said Ellen Street, EVP Cardiac Safety & Respiratory at Clario.

Clario and AliveCor collaborate to offer advanced, trial-focused six-lead ECG solutions for monitoring in decentralized clinical trials

Retrieved on: 
Tuesday, August 15, 2023
Partnership, Data collection, ECG, FDA, SVP, Kardia, PII, Clario Tech, Medical device, Mobile phone, Alivecor

PHILADELPHIA, Aug. 15, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today announced an expansion to its collaboration with AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology. This collaboration will enable trial participants to collect medical-grade six-lead ECG readings in the comfort of their own homes through KardiaRx, a clinical-trial-focused app. This technology enables pharmaceutical and biotech customers to consider decentralized and hybrid clinical trial strategies in study protocols that would have otherwise been limited to on-site evaluations.

Key Points: 
  • Clario and AliveCor provide a new trial-participant-friendly solution for cutting-edge, at-home data collection with privacy protection, instrumental in situations where traditional 12-lead ECG cannot be collected.
  • PHILADELPHIA, Aug. 15, 2023 /PRNewswire/ -- Clario , a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today announced an expansion to its collaboration with AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology.
  • This collaboration will enable trial participants to collect medical-grade six-lead ECG readings in the comfort of their own homes through KardiaRx, a clinical-trial-focused app.
  • "Our partnership with AliveCor is a game-changer for at-home ECG data collection," said Ellen Street, EVP Cardiac Safety & Respiratory at Clario.

HeartBeam Announces Publication of Foundational Study on the Detection of Heart Attacks

Retrieved on: 
Wednesday, August 9, 2023
Health, Clinical Trials, Cardiology, Medical Devices, Cardiac catheterization, Percutaneous coronary intervention, Beth Israel Deaconess Medical Center, American College of Cardiology, ST, Splenic infarction, ECG, History, Coronary occlusion, Clinical Centre of Serbia, Area, Patient, JACC, Master of Science, AUC, McGill University, AI, American College, Automated ECG interpretation, Ischemia, Credit, Medical imaging, Nursing

It demonstrated that HeartBeam’s VECG technology detects the presence of a coronary occlusion, the cause of heart attacks, with the same accuracy as a standard 12 lead electrocardiogram (12L ECG).

Key Points: 
  • It demonstrated that HeartBeam’s VECG technology detects the presence of a coronary occlusion, the cause of heart attacks, with the same accuracy as a standard 12 lead electrocardiogram (12L ECG).
  • Readings were taken before and after a 90 second balloon inflation that occluded the artery, a surrogate for a heart attack.
  • “This is the first peer-reviewed publication based on our novel VECG technology,” Branislav Vajdic, Ph.D., CEO and Founder of HeartBeam.
  • “It demonstrates the potential for an easy-to-use, patient-held device to be employed in the detection of heart attacks at home.